Altimmune Inc
Uždarymo kaina
2.93 0.34
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
2.92
Max
3.03
Pajamos | 4.8M -23M |
|---|---|
Pelnas, tenkantis vienai akcijai | -0.18 |
Pelno marža | -105,223.077 |
Darbuotojai | 57 |
EBITDA | 7.4M -21M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +336.43% upside |
Kitas uždarbis | 2026-08-11 |
|---|
Rinkos kapitalizacija | -24M 577M |
|---|---|
Ankstesnė atidarymo kaina | 2.59 |
Ankstesnė uždarymo kaina | 2.93 |
Altimmune Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.